5 High Growth Stocks Insiders Are Buying

In this article, we will list the 5 High Growth Stocks Insiders Are Buying. Please visit 10 High Growth Stocks Insiders Are Buying if you would like to see the extended list and the methodology behind it.

5. Alpha Cognition Inc. Common Stock (NASDAQ:ACOG)

On July 10, 2026, Raymond James analyst Ryan Deschner initiated coverage of Alpha Cognition Inc. (NASDAQ:ACOG) with an Outperform rating and $20 price target. Deschner noted that Alpha Cognition markets Zunveyl, a prodrug of FDA-approved galantamine indicated for the treatment of mild-to-moderate dementia in patients with Alzheimer’s disease.

Deschner said Zunveyl is designed to address a large unmet need in Alzheimer’s disease, including gastrointestinal tolerability and other adverse events that are a primary source of discontinuation for the most commonly prescribed class of Alzheimer’s disease drugs, acetylcholinesterase inhibitors.

On June 24, Alpha Cognition Inc. (NASDAQ:ACOG) announced changes to its Board of Directors. Robert Wills was elected Chairman of the Board, succeeding Len Mertz, who retired from the Board.

On June 16, Alpha Cognition announced enrollment of the first patient in RESOLVE, a Phase 4 post-marketing clinical study designed to further evaluate the tolerability profile and treatment experience associated with ZUNVEYL in routine clinical practice. The study is expected to enroll approximately 150 patients across multiple clinical sites and monitor adverse events, treatment persistence, and discontinuation rates.

Alpha Cognition Inc. (NASDAQ:ACOG) develops treatments for patients suffering from neurodegenerative diseases in the United States and Canada.